Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan

Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan

Bagsværd, Denmark, 3 December 2012 – Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.

The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the Ministry in matters related to pharmaceuticals including new drug applications. The passing of the review by the drug committee is an essential milestone in the Japanese review process prior to a marketing authorisation from the Ministry.

Novo Nordisk expects to receive marketing authorisation from the Ministry within a few months.

In Japan, price negotiations for Tresiba® (insulin degludec) continue and are expected to be completed in the first quarter of 2013. The exact launch timing for Ryzodeg® is to be decided after the Tresiba® price listing.

About Tresiba® and Ryzodeg® Tresiba® is the intended brand name for insulin degludec, the first once-daily new- generation basal insulin analogue, with an ultra-long duration of action, discovered and developed by Novo Nordisk. Tresiba® has a distinct slow absorption which provides a flat and stable action profile. Tresiba® has been studied in a large-scale clinical trial programme, BEGINTM, examining its impact on glucose control, hypoglycaemia and the possibility to flexibly adjust Tresiba® dosing time to suit patient needs.

Ryzodeg® is the intended brand name for insulin degludec/insulin aspart, which contains the new-generation basal insulin degludec in a formulation with a bolus boost of insulin aspart. Ryzodeg® is the first and only soluble insulin combination of ultra-long-acting insulin degludec and the most prescribed rapid-acting insulin, NovoRapid® (NovoLog® in the US), providing both fasting and post-prandial glucose control.

Tresiba® and Ryzodeg® were submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) in December 2011 and March 2012, respectively. Tresiba® was approved in Japan in September 2012 and in October 2012 Tresiba® and Ryzodeg® received positive CHMP opinions in Europe. In November, the products received a positive vote for approval from an FDA Advisory Committee. In addition, applications have been submitted for regulatory approval in Canada, Switzerland and a range of other countries.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information
Media:
Mike Rulis
+45 4442 3573
[email protected]
Ambre Morley (US)
+1 609 216 5240
[email protected]
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
[email protected]
Frank Daniel Mersebach
+45 4442 0604
[email protected]
Lars Borup Jacobsen
+45 3075 3479
[email protected]
Jannick Lindegaard (US)
+1 609 786 4575
[email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.